A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase of Trial: Phase I/II
Latest Information Update: 29 Dec 2018
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 24 Jul 2018 Planned primary completion date changed from 28 Oct 2020 to 29 May 2020.
- 02 Jul 2018 Planned End Date changed from 28 Oct 2020 to 29 May 2020.
- 02 Nov 2017 Status changed from not yet recruiting to recruiting.